Data sharing going on with WHO to give recognition to Covaxin: Govt

Responding to a question on recognition of Covaxin by the WHO, NITI Aayog Member (Health) V K Paul said the government is pursuing it.

Covaxin
Covaxin (Photo: Bloomberg)
Press Trust of India New Delhi
2 min read Last Updated : Jun 04 2021 | 8:19 PM IST

Data sharing is going on with WHO to give recognition to Bharat Biotech's Covaxin, the government said, noting that it wants to achieve this "milestone" as soon as possible.

Responding to a question on recognition of Covaxin by the WHO, NITI Aayog Member (Health) V K Paul said the government is pursuing it.

"We have been working with both Bharat Biotech and the WHO to make it happen. There is data sharing going on and we are very keen that this milestone is achieved as soon as possible. We are pursuing it," he said.

On May 24, Hyderabad-based Bharat Biotech International Limited (BBIL) conveyed to the government that it has already submitted 90 per cent of the documents to the WHO for obtaining emergency use listing (EUL) for the Covaxin vaccine.

The latest 'Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process' guidance document dated May 18 on the WHO website said Bharat Biotech submitted EOI (Expression of Interest) on April 19 and that "more information (is) required".

A pre-submission meeting is expected "to be planned May-June 2021", the guidance document said.

According to the WHO, submissions to it for prequalification or listing under the emergency use procedure are confidential.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jun 04 2021 | 8:18 PM IST

Next Story